Table 4.
Summarized properties of discussed vaccine technologies.
| Viral vector based vaccines | DNA vaccines | RNA vaccines | |
|---|---|---|---|
| Platform versatility | + | + | + |
| Induction of cellular and humoral immune responses | + | + | + |
| Fully synthetic vaccine production possible | – | + | + |
| Delivery as minimal vaccine construct possible* | – | ± | + |
| Repeated vaccine applications possible | ± | + | + |
| Vaccine safety | ± | + | ++ |
| Immunogenicity demonstrated in clinical studies | + | ± | ± |
*
Minimal construct: the vaccine exclusively encodes the target antigen.